Clinical Trials Browser

Endometrial Neoplasms

NCT04446416 2026-04-09

Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients

Phase NA Completed

6 enrolled

CNS

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue

NCT01445509 2026-04-06

Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors

Phase 1 Completed

50 enrolled

Tumor-Agnostic

Neoplasms

NCT06812871 2026-04-02

High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

Phase 2 Completed

46 enrolled

CNS

Meningeal Carcinomatosis

NCT03798626 2026-04-01

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Phase 1 Completed

167 enrolled

GastrointestinalGenitourinary

Carcinoma, Renal Cell, Colorectal Neoplasms

NCT05359861 2026-03-18

Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma

Phase 2 Completed

30 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms

NCT01303497 2026-03-13

ANGIO-TAX+

Phase 2 Completed

70 enrolled

Sarcoma

Hemangiosarcoma

NCT05665348 2026-03-09

TRIPLET

Phase 2/3 Completed

229 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasm Metastasis

NCT05263947 2026-02-24

Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation

Phase 2 Completed

35 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02669173 2026-02-23

Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma

Phase 1 Completed

12 enrolled

CNS

Brain Neoplasms, Glioblastoma, Recurrence

NCT04109924 2026-02-10

TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study

Phase 2 Completed

42 enrolled 12 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT03133546 2026-02-06

BOOSTER

Phase 2 Completed

155 enrolled 23 charts

Thoracic

Non Small Cell Lung Cancer Metastatic

NCT04813913 2026-02-06

VASCATAQ

Phase 4 Completed

13 enrolled

Tumor-Agnostic

Neoplasms

NCT03635567 2026-02-04

KEYNOTE-826

Phase 3 Completed

617 enrolled 29 charts 2 FDA

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT00826540 2026-01-20

Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Phase 2 Completed

83 enrolled 10 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

Clinical Trials

EndoBARR

Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients

Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors

High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma

ANGIO-TAX+

TRIPLET

Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation

Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma

TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study

BOOSTER

VASCATAQ

KEYNOTE-826

Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer